NEW YORK (GenomeWeb News) – CombiMatrix has been warned by Nasdaq that it doesn't meet a requirement to remain being listed on the exchange, the Irvine, Calif.-based firm said after the close of the market on Friday.

CombiMatrix said that it received a notification dated June 26 from the Listing Qualifications department of Nasdaq telling the company that it was in violation of a listing requirement calling for a minimum bid of $1 per share, "based upon the closing bid price for the last 30 consecutive business days."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.